Research graph
References from The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers. Local targets link to admitted publications; unresolved targets remain external evidence.
Childhood cancer
2025 · External reference
The landscape of genomic alterations across childhood cancers
10.1038/nature25480 · 2018 · External reference
Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours
10.1038/nature25795 · 2018 · External reference
DNA methylation-based classification of central nervous system tumours
10.1038/nature26000 · 2018 · External reference
Sarcoma classification by DNA methylation profiling
10.1038/s41467-020-20603-4 · 2021 · External reference
A summary of the inaugural WHO classification of pediatric tumors: transitioning from the optical into the molecular era
10.1158/2159-8290.cd-21-1094 · 2022 · External reference
Advancing CNS tumor diagnostics with expanded DNA methylation-based classification
10.1016/j.ccell.2025.11.002 · 2026 · External reference
The pediatric precision oncology INFORM registry: clinical outcome and benefit for patients with very high-evidence targets
10.1158/2159-8290.cd-21-0094 · 2021 · External reference
The European MAPPYACTS trial: precision medicine program in pediatric and adolescent patients with recurrent malignancies
10.1158/2159-8290.cd-21-1136 · 2022 · External reference
The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations
10.1038/s43018-022-00474-y · 2023 · External reference
Diagnostic classification of childhood cancer using multiscale transcriptomics
10.1038/s41591-023-02221-x · 2023 · External reference
Precision-guided treatment in high-risk pediatric cancers
10.1038/s41591-024-03044-0 · 2024 · External reference
The RACE act and pediatric trials of adult cancer drugs
10.1542/peds.2024-066920 · 2024 · External reference
Genomic profiling of childhood tumor patient-derived xenograft models to enable rational clinical trial design
10.1016/j.celrep.2019.09.071 · 2019 · External reference
A biobank of patient-derived pediatric brain tumor models
10.1038/s41591-018-0207-3 · 2018 · External reference
Orthotopic patient-derived xenografts of paediatric solid tumours
10.1038/nature23647 · 2017 · External reference
A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors
10.1038/s42003-023-05320-0 · 2023 · External reference
Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors
10.1093/annonc/mdx416 · 2017 · External reference
Patient-derived xenograft models in cancer therapy: technologies and applications
10.1038/s41392-023-01419-2 · 2023 · External reference
Patient-derived xenograft models: an emerging platform for translational cancer research
10.1158/2159-8290.cd-14-0001 · 2014 · External reference
Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ
10.1016/j.celrep.2012.12.013 · 2013 · External reference
Patient-derived xenografts for individualized care in advanced sarcoma
10.1002/cncr.28696 · 2014 · External reference
Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas
10.1002/cjp2.210 · 2021 · External reference
Genomic profiling of subcutaneous patient-derived xenografts reveals immune constraints on tumor evolution in childhood solid cancer
10.1038/s41467-023-43373-1 · 2023 · External reference
Establishing a pediatric solid tumor PDX biobank for precision oncology research
10.1080/15384047.2025.2541974 · 2025 · External reference
Evaluation of alternative in vivo drug screening methodology: a single mouse analysis
10.1158/0008-5472.can-16-0122 · 2016 · External reference
Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours
10.1038/s41568-019-0169-x · 2019 · External reference
A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data
10.1093/bioinformatics/btr509 · 2011 · External reference
Accurate and efficient detection of gene fusions from RNA sequencing data
10.1101/gr.257246.119 · 2021 · External reference
Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
10.1136/jitc-2019-000147 · 2020 · External reference
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
10.1038/nm.3954 · 2015 · External reference
A mechanistic classification of clinical phenotypes in neuroblastoma
10.1126/science.aat6768 · 2018 · External reference
Integrative genome-scale analysis identifies epigenetic mechanisms of transcriptional deregulation in unfavorable neuroblastomas
10.1158/0008-5472.can-15-2507 · 2016 · External reference
Genetic and epigenetic regulation of gene expression in fetal and adult human livers
10.1186/1471-2164-15-860 · 2014 · External reference
An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity
10.1038/s41467-020-15155-6 · 2020 · External reference
Insights into the pathogenesis of anaplastic large-cell lymphoma through genome-wide DNA methylation profiling
10.1016/j.celrep.2016.09.018 · 2016 · External reference
The 2021 WHO classification of tumors of the central nervous system: a summary
10.1093/neuonc/noab106 · 2021 · External reference
DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma
10.1038/nm.4273 · 2017 · External reference
Tumor purity in preclinical mouse tumor models
10.1158/2767-9764.crc-21-0126 · 2022 · External reference
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
10.1038/ng.3333 · 2015 · External reference
Neuroblastoma
10.1038/nrdp.2016.78 · 2016 · External reference
Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations
10.1158/2159-8290.cd-14-0622 · 2014 · External reference
Combination therapies targeting ALK-aberrant neuroblastoma in preclinical models
10.1158/1078-0432.ccr-22-2274 · 2023 · External reference
Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment
10.1038/s41467-021-25177-3 · 2021 · External reference
Author correction: developmental origins shape the paediatric cancer genome
10.1038/s41568-024-00710-w · 2024 · External reference
The ongoing trends of patient-derived xenograft models in oncology
10.1002/cac2.12096 · 2020 · External reference
